


Foot-and-mouth disease diagnostics:


...are we there yet?

Donald King

Molecular Characterisation and Diagnostics Group, IAH



Where we've been



Laboratory diagnosis of FMD

Approaches:

- Detection of FMD virus
- Detection of FMDV-specific antibody (SP/NSP)
- Samples collected:
 - Tissue (vesicular epithelium)
 - Blood (sera or whole blood)

 - “probang” samples
 - Milk
 - Swabs from mucosal surfaces
 - Environmental samples (air samples etc..)




Diagnostic windows

What are we trying to do?

② Active surveillance for infected animals (including pre-clinical cases)

① Rapid confirmation of clinical signs

③ sero-surveillance for FMDV exposed animals




Current assays for FMDV detection




Virus
isolation
(CTY or IBRS2)

1-4 days



Ag ELISA

~4 hours



Automated
TaqMan®
RT-PCR

~5 hours

1


10

100

Time to report result (hrs)



New assay formats: considerations



Routine use in WRL

- Reliability
- Performance
 - Limit of detection
 - Ability to correctly identify infected animals with diverse FMDV strains
- Speed
- Scalability
- Cost ?

The road ahead.....

Foresight

Making the future work for you

OFFICE OF SCIENCE AND INNOVATION

Infectious Diseases:

preparing for the future

<http://www.foresight.gov.uk/>



Molecular Characterisation & Diagnostics Group

What can we expect?

Technologies

Improvements in:


- Computer power
- Communications
- Detector chemistries
- Sequencing capability


Drivers for Change

- Tools to support rapid decision making
 - “Point-of-care diagnostics”
 - Highly parallel assay formats for:
 - [i] differential diagnosis
 - [ii] strain characterisation



Lateral-flow devices FMDV Antigen detection

- Developed by IAH in collaboration with international partners
- Quick and simple to perform
- Pan-serotypic
- During 2007: used for rapid (<10 mins) confirmation of FMD in the field (IP7)
- Also useful in the Lab
- LFD marketed by 



Validation data for pan-reactive LFD

- Sensitivity data generated for archived clinical samples

Virus serotype	ELISA		1F10 (gold-particle)	
	Fraction	%	Fraction	%
FMDV type O	121/126	96	119/129	92.2
FMDV type A	32/41	78	36/41	87.8
FMDV type C	14/24	58.3	15/24	62.5
FMDV type SAT 1	13/24	54.2	16/24	66.7
FMDV type SAT 2	28/32	87.5	18/32	56.3
FMDV type SAT 3	9/10	90	7/10	70
FMDV type Asia 1	36/40	90	39/40	97.5
Total	253/297	85.2	250/300	83.3



Rapid detection of FMDV in the field: Portable PCR platform



- Non-specialist user
 - Nucleic acid extraction
 - PCR set-up
 - Analysis
- 5 independent modules
- Battery operated
- Decontaminate by immersion
- Field trial (Turkey) later in 2008
- Platform for other livestock diseases



Smiths Bio-Seq™

Molecular Characterisation & Diagnostics Group

Rapid communication of results



Non-invasive sampling



BioCapture 650



BioBadge 100

- Air-samplers (MesoSystems)
- Hand held
- Simple-to-use

	BioCapture	BioBadge
Cattle 3 dpi	10.24	11.23


Log₁₀ FMDV copies detected by rRT-PCR after 5 minute collection near animals infected with FMDV (serotype Asia-1) (Ryan et al., 2007)

- Integrated with FMDV detector?
- located in high-risk areas?

Alternative detector technologies

Isothermal amplification (RT-LAMP)

- Nucleic acid amplification at a single temperature
- No need for fragile precision instrumentation
- Basis of disposable device / cost effective
- More suitable for use in the field
- Very rapid, similar sensitivity to RT-PCR



Detection and characterisation?

Viral MicroArray

Potential Benefits:



- Thousands of experiments in parallel
- Differential diagnosis
- Viral Typing of FMDV isolates
- Clarification of mixed infections
- Portable formats emerging

DEFRA funded Biochip project (April 06-09)



<http://www.bio-chip.co.uk/>

O UKG 12/2001



Molecular Characterisation & Diagnostics Group

Potential scenario for field diagnosis of FMD

Veterinary visit



**Clinical
diagnosis**

Lateral-flow devices (LFDs)
Sensitivity ~80%



- Rapid confirmation of positives?

“Rapid” Molecular assays
Sensitivity >95%



- Ability to confirm negatives
- Additional surveillance use
- Strain characterisation?



Future challenges

- Rapid development of technologies
- Key role of commercial partners
 - Is the market viable?
- Use in FMD-endemic countries
- Availability of technology
 - Provide freely vs control of local diagnosis/ reporting for notifiable diseases



Summary and Prospects:

1. FMDV-specific assays have been developed to address wide range of clinical circumstances
 - Role of WRL for assay validation
2. Likely to be increased demand for testing in future
 - Active surveillance for disease in high risk animals
 - Pre-clinical testing
 - Integration of different assay formats (viral/sero)
3. Devolved and POC formats offer potential to significantly decrease assay time
 - Support of diagnosis based on clinical signs
 - Involvement of end-users and stakeholders is vital



Acknowledgements



- Scott Reid
- Katja Ebert
- Heather James
- Nigel Ferris
- Geoff Hutchings
- Juliet Dukes
- Nick Knowles
- Satya Parida
- John Gloster
- David Paton

